<DOC>
	<DOCNO>NCT02794636</DOCNO>
	<brief_summary>The primary objective study quantify compare prevalence adverse event ( AEs ) patient stage III melanoma initiation interferon ( IFN ) therapy real-world setting . A secondary objective quantify annual cost resource utilization IFN initiation among patient stage III melanoma real-world setting .</brief_summary>
	<brief_title>Interferon Toxicities Melanoma Treatment</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<criteria>Patients pharmacy claim IFN 1/1/2007 12/31/2011 . The date first observe claim define index date Patients melanoma diagnosis base two medical claim prior index date Patients procedure code melanomarelated lymph node dissection index date Patients â‰¥ 18 year age index date Patients continuous benefit enrollment least 180 day index date Patients diagnosis ( primary ) cancer 180day preindex period ( except skin cancer hematologic malignancy ) Patients diagnosis secondary cancer 180day preindex period index date ( except lymph node metastasis site common melanoma improbable site primary cancer ) Patients received systemic chemotherapy pre postindex period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>